A global leader in serving libraries of all types, ProQuest LLC (“ProQuest”) supports the breadth of the information community with innovative discovery solutions that power the business of books and the best in research experience. More than a content provider or aggregator, ProQuest is an information partner, creating indispensable research solutions that connect people and information. Through innovative, user-centered discovery technology, ProQuest offers billions of pages of global content that includes historical newspapers, dissertations, and uniquely relevant resources for researchers of any age and sophistication—including content not likely to be digitized by others.
000A20_MPR_0210.qxp 2/5/2010 10:49 AM Page 1 PIPELINE Highlights of progress in drug development Cardiovascular CCX354 (from ChemoCentryx) a selective AMR101 (from Amarin) an ultra-pure CCR1 chemokine receptor antagonist omega-3 form developed with ethyl ester being evaluated for the treatment of of eicosapentaenoic acid being studied for rheumatoid arthritis—Phase 2 treating hypertriglyceridemia—Phase 3 SBI-087 (from Trubion) a humanized CNS Small Modular ImmunoPharmaceutical EVP-6124 (from EnVivo) a selective (SMIP) protein therapeutically directed nicotinic acetylcholine receptor subtype against the CD20 antigen being developed alpha-7 agonist being investigated for for treating rheumatoid arthritis—Phase 2 treating schizophrenia—Phase 2b Nutrition Lurasidone (from Dainippon Sumitomo) Phentermine + topiramate (Qnexa, from an atypical antipsychotic being assessed Vivus) a controlled-release formulation of for the treatment of schizophrenia— phentermine and topiramate being NDA submitted reviewed for treating obesity, including weight loss and maintenance of weight Retigabine (from Valeant) a neuronal loss, in obese or overweight patients with potassium channel opener being reviewed comorbidities such as hypertension, as an adjunctive treatment for partial- type 2 diabetes, dyslipidemia or central onset seizures in adults—NDA accepted adiposity—NDA submitted Dermatological disorders Oncology Apremilast (from Celgene) an orally ADXS11-001 (from Advaxis) a therapeutic avail
Pages to are hidden for
"PIPELINE 000A20 MPR 0210 qxp 2 5 2010 10"Please download to view full document